.webp)
67/100B67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Royalty Pharma debt to equity ratioWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
Royalty Pharma's debt to equity ratio is 1.26: total debt of 8.59B USD against shareholders' equity of 6.84B USD.
- Today
- 1.26
- Average, 5 years
- 1.18
- Low, 5 years
- 0.94
- High, 5 years
- 1.40
Debt to equity = total debt ÷ shareholders' equity = 8.59B ÷ 6.84B = 1.26
Debt to equity
Total debt
Shareholders' equity
Total debt over shareholders' equity at each quarter end.
Debt to equity by year and by quarter
| Fiscal year | Period ending | Debt to equity | Total debt | Shareholders' equity |
|---|---|---|---|---|
| Today | 1.26 | 8.59B | 6.84B | |
| FY2025 | 31 Dec 2025 | 1.38 | 8.95B | 6.48B |
| FY2024 | 31 Dec 2024 | 1.10 | 7.61B | 6.95B |
| FY2023 | 31 Dec 2023 | 0.94 | 6.14B | 6.53B |
| FY2022 | 31 Dec 2022 | 1.26 | 7.12B | 5.63B |
| FY2021 | 31 Dec 2021 | 1.23 | 7.10B | 5.78B |
| FY2020 | 31 Dec 2020 | 1.21 | 5.82B | 4.82B |
| FY2019 | 31 Dec 2019 | 1.02 | 6.24B | 6.11B |
| FY2018 | 31 Dec 2018 | 1.45 | 6.52B | 4.49B |
| FY2017 | 31 Dec 2017 | 1.52 | 6.80B | 4.46B |
| FY2016 | 31 Dec 2016 | 1.33 | 5.90B | 4.45B |
| FY2015 | 31 Dec 2015 | 1.28 | 5.99B | 4.68B |
| Quarter | Period ending | Debt to equity | Total debt | Shareholders' equity |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 1.26 | 8.59B | 6.84B |
| Q2 FY2026 | 30 Jun 2026 | 1.31 | 8.96B | 6.83B |
| Q1 FY2026 | 31 Mar 2026 | 1.30 | 8.96B | 6.89B |
| Q4 FY2025 | 31 Dec 2025 | 1.38 | 8.95B | 6.48B |
| Q3 FY2025 | 30 Sept 2025 | 1.40 | 8.97B | 6.41B |
| Q2 FY2025 | 30 Jun 2025 | 1.26 | 8.00B | 6.35B |
| Q1 FY2025 | 31 Mar 2025 | 1.14 | 7.62B | 6.69B |
| Q4 FY2024 | 31 Dec 2024 | 1.10 | 7.61B | 6.95B |
| Q3 FY2024 | 30 Sept 2024 | 1.11 | 7.61B | 6.87B |
| Q2 FY2024 | 30 Jun 2024 | 1.17 | 7.60B | 6.48B |
| Q1 FY2024 | 31 Mar 2024 | 0.94 | 6.14B | 6.50B |
| Q4 FY2023 | 31 Dec 2023 | 0.94 | 6.14B | 6.53B |
| Q3 FY2023 | 30 Sept 2023 | 1.00 | 6.13B | 6.14B |
| Q2 FY2023 | 30 Jun 2023 | 1.13 | 7.13B | 6.28B |
| Q1 FY2023 | 31 Mar 2023 | 1.20 | 7.12B | 5.95B |
| Q4 FY2022 | 31 Dec 2022 | 1.26 | 7.12B | 5.63B |
| Q3 FY2022 | 30 Sept 2022 | 1.16 | 7.11B | 6.15B |
| Q2 FY2022 | 30 Jun 2022 | 1.18 | 7.11B | 6.03B |
| Q1 FY2022 | 31 Mar 2022 | 1.23 | 7.10B | 5.78B |
| Q4 FY2021 | 31 Dec 2021 | 1.23 | 7.10B | 5.78B |
| Q3 FY2021 | 30 Sept 2021 | 1.22 | 7.09B | 5.79B |
| Q2 FY2021 | 30 Jun 2021 | 1.02 | 5.83B | 5.73B |
| Q1 FY2021 | 31 Mar 2021 | 1.19 | 5.82B | 4.88B |
| Q4 FY2020 | 31 Dec 2020 | 1.21 | 5.82B | 4.82B |
| Q3 FY2020 | 30 Sept 2020 | 1.31 | 5.81B | 4.45B |
| Q2 FY2020 | 30 Jun 2020 | 1.42 | 5.91B | 4.16B |
| Q1 FY2020 | 31 Mar 2020 | 1.15 | 5.96B | 5.16B |
| Q4 FY2019 | 31 Dec 2019 | 1.02 | 6.24B | 6.11B |
| Q3 FY2019 | 30 Sept 2019 | — | — | — |
| Q2 FY2019 | 30 Jun 2019 | — | — | — |
| Q1 FY2019 | 31 Mar 2019 | 0.00 | 0.00 | 4.55B |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Current ratio,All ratios
Common questions about Royalty Pharma's debt to equity
Source: Financial Modeling Prep